Abstract
The radiolabelled amino acid analogue L-3-[I-125]iodo-alpha-methyl-tyrosine (IMT) is under evaluation in brain tumours, where it reflects amino acid transport activity, but is also taken up in many other tumour types. This study investigated the uptake mechanism of IMT in tumour cells not derived from brain tumours, in comparison with the native amino acid C-14-tyrosine (Tyr) from which IMT is derived. Human GLC4 small-cell lung cancer cells in log-phase were incubated with IMT and Tyr. Tracer uptake was determined in various buffers, incubation periods, concentrations of specific amino acid transport blockers, pH and temperature. IMT uptake was very fast, reaching a plateau within 5 min, while Tyr kept on accumulating for > 60 min. Based on steady-state experiments, > 90% of IMT uptake could be attributed to amino acid transport activity. The L transport system was the most important, both fur IMT and Tyr. IMT uptake into GLC4 tumour cells is almost completely the result of amino acid transport activity (especially the L system) and is very similar to Tyr uptake. Therefore, also outside the brain, IMT is a metabolic tracer that may reflect the increased amino acid transport that is characteristic for malignant tumours. ((C) 2001 Lippincott Williams & Wilkins).
| Original language | English |
|---|---|
| Pages (from-to) | 87-96 |
| Number of pages | 10 |
| Journal | Nuclear Medicine Communications |
| Volume | 22 |
| Issue number | 1 |
| Publication status | Published - Jan-2001 |
Keywords
- iodo-methyl-tyrosine
- tyrosine
- amino acid transport
- uptake mechanism
- GLC4 tumor cells
- AMINO-ACID-TRANSPORT
- BREAST-CANCER
- L-TYROSINE
- C-11 METHIONINE
- IN-VIVO
- PET
- BRAIN
- TUMORS
- CARBON-11-METHIONINE
- METABOLISM